Acceptability and feasibility of medical abortion in Nepal

International Journal of Gynecology and Obstetrics

Volumn 106, Issue 1, 2009, Pages 39-42

  Karki, Chanda ^a   Pokharel, Hanoon ^b   Kushwaha, Anu ^c   Manandhar, Durga ^d   Bracken, Hillary ^e   Winikoff, Beverly ^e  

^a KATHMANDU MEDICAL COLLEGE TEACHING HOSPITAL   (Nepal)

^b B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^c Family Planning Association of Nepal   (Nepal)

^d Baluwatar   (Nepal)

^e GYNUITY HEALTH PROJECTS   (United States)

Author keywords

Medical abortion; Mifepristone; Misoprostol; Nepal

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEALTH SERVICE; HOME CARE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MEDICAL ABORTION; NEPAL; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

EID: 67349258541     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2009.02.007     Document Type: Article

References (12)

1. Ministry of Health and Population, Department of Health Services, and Family Health Division. Unsafe Abortion: Nepal Country Profile (2006), Government of Nepal, Kathmandu
2. Leeman L., Asaria S., Espey E., Ogburn J., Gopman S., and Barnett S. Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion?. Contraception 76 2 (2007) 96-100
3. Mundle S., Elul B., Anand A., Kalyanwala S., and Ughade S. Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center. Contraception 76 1 (2007) 66-70
4. Hajri S., Blum J., Gueddana N., Saadi H., Maazoun L., Chélli H., et al. Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study. Contraception 70 6 (2004) 487-491
5. Elul B., Hajri S., Ngoc N.N., Ellertson C., Slama C.B., Pearlman E., et al. Can women in less-developed countries use a simplified medical abortion regimen?. Lancet 357 9266 (2001) 1402-1405
6. Fiala C., Winikoff B., Helström L., Hellborg M., and Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical abortion. Contraception 70 5 (2004) 387-392
7. Clark W.H., Gold M., Grossman D., and Winikoff B. Can mifepristone medical abortion be simplified? A review of evidence and questions for future research. Contraception 75 4 (2007) 245-250
8. Winikoff B., Sivin I., Coyaji K.J., Cabezas E., Xiao B., Gu S., et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol 176 2 (1997) 431-437
9. Winikoff B., Dzuba I.G., Creinin M.D., Crowden W.A., Goldberg A.B., Gonzales J., et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 112 6 (2008) 1303-1310
10. Tang O.S., Chan C.C., Ng E.H., Lee S.W., and Ho P.C. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 18 11 (2003) 2315-2318
11. Hamoda H., Ashok P.W., Dow J., Flett G.M., and Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception 68 5 (2003) 335-338
12. Hamoda H., Ashok P.W., Flett G.M., and Templeton A. A randomized controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 112 8 (2005) 1102-1108